Literature DB >> 12643175

Hepatic steatosis and type 2 diabetes mellitus.

Jeanne M Clark1, Anna Mae Diehl.   

Abstract

Type 2 diabetes is strongly associated with nonalcoholic fatty liver disease (NAFLD), a spectrum of liver damage that ranges from relatively benign hepatic steatosis to potentially fatal cirrhosis. The severities of insulin resistance and liver damage parallel each other, with the greatest prevalence of cirrhosis occurring in cirrhotics. However, it is unknown whether one of these conditions causes the other, or if both are consequences of another process. Experimental evidence suggests that both insulin resistance and NAFLD result from a chronic inflammatory state. The mechanisms driving this chronic inflammation are unknown but might include the egress of products from intestinal bacteria into the portal blood, liver, and systemic circulation to trigger a sustained inflammatory cytokine response in genetically susceptible individuals. More research is needed to evaluate this hypothesis and to determine the benefits of treatments that interrupt this pathogenic cascade.

Entities:  

Mesh:

Year:  2002        PMID: 12643175     DOI: 10.1007/s11892-002-0085-3

Source DB:  PubMed          Journal:  Curr Diab Rep        ISSN: 1534-4827            Impact factor:   4.810


  57 in total

1.  Liver fibrosis in overweight patients.

Authors:  V Ratziu; P Giral; F Charlotte; E Bruckert; V Thibault; I Theodorou; L Khalil; G Turpin; P Opolon; T Poynard
Journal:  Gastroenterology       Date:  2000-06       Impact factor: 22.682

2.  The liver in obesity.

Authors:  S ZELMAN
Journal:  AMA Arch Intern Med       Date:  1952-08

3.  Prevalence of fatty liver in a general population of Okinawa, Japan.

Authors:  H Nomura; S Kashiwagi; J Hayashi; W Kajiyama; S Tani; M Goto
Journal:  Jpn J Med       Date:  1988-05

Review 4.  Cytokine regulation of liver injury and repair.

Authors:  A M Diehl
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

5.  Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults. The Third National Health and Nutrition Examination Survey, 1988-1994.

Authors:  M I Harris; K M Flegal; C C Cowie; M S Eberhardt; D E Goldstein; R R Little; H M Wiedmeyer; D D Byrd-Holt
Journal:  Diabetes Care       Date:  1998-04       Impact factor: 19.112

6.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

7.  Metformin reverses fatty liver disease in obese, leptin-deficient mice.

Authors:  H Z Lin; S Q Yang; C Chuckaree; F Kuhajda; G Ronnet; A M Diehl
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

8.  Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people.

Authors:  E Ikai; M Ishizaki; Y Suzuki; M Ishida; Y Noborizaka; Y Yamada
Journal:  J Hum Hypertens       Date:  1995-02       Impact factor: 3.012

9.  Cause-specific mortality in a population-based study of diabetes.

Authors:  S E Moss; R Klein; B E Klein
Journal:  Am J Public Health       Date:  1991-09       Impact factor: 9.308

10.  Nonalcoholic steatohepatitis: an expanded clinical entity.

Authors:  B R Bacon; M J Farahvash; C G Janney; B A Neuschwander-Tetri
Journal:  Gastroenterology       Date:  1994-10       Impact factor: 22.682

View more
  33 in total

Review 1.  Steatosis in chronic hepatitis C: why does it really matter?

Authors:  T Asselah; L Rubbia-Brandt; P Marcellin; F Negro
Journal:  Gut       Date:  2006-01       Impact factor: 23.059

2.  Exendin-4 attenuates endoplasmic reticulum stress through a SIRT1-dependent mechanism.

Authors:  Jinmi Lee; Seok-Woo Hong; Se Eun Park; Eun-Jung Rhee; Cheol-Young Park; Ki-Won Oh; Sung-Woo Park; Won-Young Lee
Journal:  Cell Stress Chaperones       Date:  2014-01-21       Impact factor: 3.667

3.  Effect of Restriction of Foods with High Fructose Corn Syrup Content on Metabolic Indices and Fatty Liver in Obese Children.

Authors:  Lorena Del Rocio Ibarra-Reynoso; Hilda Lissette López-Lemus; Ma Eugenia Garay-Sevilla; Juan Manuel Malacara
Journal:  Obes Facts       Date:  2017-08-05       Impact factor: 3.942

4.  Effects of insulin treatment on intracellular lipid metabolism in liver of diabetic rats.

Authors:  Lulu Chen; Yongbo Wang; Min Zhou; Baoping Wang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2006

Review 5.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance.

Authors:  Sutapa Banerjee; Kousuke Saito; Malika Ait-Goughoulte; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

Review 7.  Diabetic dyslipidaemia: from basic research to clinical practice.

Authors:  M-R Taskinen
Journal:  Diabetologia       Date:  2003-05-28       Impact factor: 10.122

8.  Selective hepatic insulin resistance in a murine model heterozygous for a mitochondrial trifunctional protein defect.

Authors:  R Scott Rector; E Matthew Morris; Suzanne Ridenhour; Grace M Meers; Fong-Fu Hsu; John Turk; Jamal A Ibdah
Journal:  Hepatology       Date:  2013-04-26       Impact factor: 17.425

Review 9.  Biochemical mechanisms in drug-induced liver injury: certainties and doubts.

Authors:  Ignazio Grattagliano; Leonilde Bonfrate; Catia V Diogo; Helen H Wang; David Q H Wang; Piero Portincasa
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

10.  Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected].

Authors:  Bangyan Stiles; Ying Wang; Andreas Stahl; Sara Bassilian; W Paul Lee; Yoon-Jung Kim; Robert Sherwin; Sherin Devaskar; Ralf Lesche; Mark A Magnuson; Hong Wu
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-09       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.